Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
Regulus (RGLS) Stock Price & Analysis
435 Followers
RGLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $3.79
Previous Close$2.02
Volume153.58K
Average Volume (3M)3.28M
Market Cap
$133.55M
Enterprise Value$104.83M
Total Cash (Recent Filing)$30.78M
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)-1.4
Beta0.86
Next Earnings
Aug 08, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding65,465,876
10 Day Avg. Volume614,858
30 Day Avg. Volume3,277,240
Standard Deviation0.29
R-Squared0.08
Alpha-0.00764
Financial Highlights & Ratios
Price to Book (P/B)1.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.28
Forecast
1Y Price Target
$7.25Price Target Upside255.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Regulus News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressLead asset RGLS8429 shows steady progress in treating autosomal dominant polycystic kidney disease, with positive topline data from Cohort 1 and Cohort 2 indicating reductions in key disease markers and early positive signals on kidney endpoints.
Financial StabilityWith $107.7M in cash on hand, Regulus Therapeutics has secured a strong financial position, expected to fund operations into the first half of 2026, enhancing the company's ability to continue its research and development efforts without financial constraints.
Market ConfidenceAnalysts maintain a BUY recommendation for Regulus Therapeutics, with a $11 price target, reflecting a strong vote of confidence in the stock's potential and the company's ongoing commitment to addressing autosomal dominant polycystic kidney disease.
Bears Say
Analyst's ExpectationsThe net effect of changes is a decrease in price target.
Financial PerformanceNet loss totaled $8.5M.
Future ExpectationsCohort 3 data expected.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $1.08 and its highest was $3.79 in the past 12 months.
What is Regulus’s market cap?
Currently, no data Available
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is Aug 08, 2024 which is in 84 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on May 09, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.222 by -$0.068.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -$0.13.
How many shares outstanding does Regulus have?
Regulus has 65,465,870 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.222. Following the earnings report the stock price went down -1.778%.
Which hedge fund is a major shareholder of Regulus?
Currently, no hedge funds are holding shares in RGLS
---
Regulus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (255.39% Upside)
$7.25 (255.39% Upside)
Blogger Sentiment
Bullish
RGLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 24.2%
Last 30 Days ▲ 24.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.32%
12-Months-Change
Fundamentals
Return on Equity
-46.75%
Trailing 12-Months
Asset Growth
208.36%
Trailing 12-Months
Company Description
Regulus
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
---
RGLS Earnings Call
Q3 2022
0:00 / 0:00
---
RGLS Stock 12 Month Forecast
Average Price Target
$7.25
▲(255.39% Upside)
Technical Analysis
Seres Therapeutics
―
Rocket Pharmaceuticals
―
Axsome Therapeutics
―
Kezar Life Sciences
―
Best Analysts Covering RGLS
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+21.48%
reiterated a buy rating 7 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +21.48% per trade.
---